OncoDaily IO· @OncoDailyIO · X·· 23 小时前评分70
正文 · 原文
🧬 GDFather-NEO: Neoadjuvant visugromab + nivolumab yielded a locally assessed pCR of 33.3% vs 7.7% with nivolumab alone in MIBC.
Exploratory, nonrandomized phase II findings warrant randomized validation; an EFS benefit remains unproven.
https://oncodaily.com/oncolibrary/immune-oncology/gdfather-neo
#ESMO2026 #OncoDail #GDFatherNEO
20 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
4757RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上
Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.org来源：OncoDaily IO · x.com